Cargando…
MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines
Lung cancer is one of the most common deadly diseases worldwide, most of which is non-small cell lung cancer (NSCLC). The epidermal growth factor receptor (EGFR) mutant NSCLCs frequently respond to the EGFR tyrosine kinase inhibitors (EGFR-TKIs) treatment, such as Gefitinib and Erlotinib, but the de...
Autores principales: | Meng, Fei, Wang, Fengfeng, Wang, Lili, Wong, S. C. Cesar, Cho, William C. S., Chan, Lawrence W. C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108768/ https://www.ncbi.nlm.nih.gov/pubmed/27895663 http://dx.doi.org/10.3389/fgene.2016.00197 |
Ejemplares similares
-
Combination therapy of gefitinib and miR-30a-5p may overcome acquired
drug resistance through regulating the PI3K/AKT pathway in non-small cell lung
cancer
por: Wang, Fengfeng, et al.
Publicado: (2020) -
MiR-30 Family Potentially Targeting PI3K-SIAH2 Predicted Interaction Network Represents a Novel Putative Theranostic Panel in Non-small Cell Lung Cancer
por: Chan, Lawrence W. C., et al.
Publicado: (2017) -
Associations of mRNA:microRNA for the Shared Downstream Molecules of EGFR and Alternative Tyrosine Kinase Receptors in Non-small Cell Lung Cancer
por: Wang, Fengfeng, et al.
Publicado: (2016) -
miR-30b-3p Inhibits Proliferation and Invasion of Hepatocellular Carcinoma Cells via Suppressing PI3K/Akt Pathway
por: Gao, Dongkai, et al.
Publicado: (2019) -
Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
por: Bartholomeusz, Chandra, et al.
Publicado: (2011)